Sonoma Pharmaceuticals Inc Cash Flow Conversion Efficiency
Sonoma Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has a cash flow conversion efficiency ratio of -0.098x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-649.00K) by net assets ($6.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sonoma Pharmaceuticals Inc (2005–2026)
Cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2026. This chart illustrates how Sonoma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sonoma Pharmaceuticals Inc (SNOA) stock price for real-time trading data and today's change.
Sonoma Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Sonoma Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sonoma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see market value of Sonoma Pharmaceuticals Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compodium International AB
ST:COMPDM
|
0.015x |
|
Fidelity Minerals Corp
V:FMN
|
-0.029x |
|
Philly Shipyard ASA
OL:PHLY
|
-4.976x |
|
COLLPLANT BIOTECH. IS-01
F:CPT
|
-0.624x |
|
Narryer Metals Ltd
AU:NYM
|
-0.261x |
|
Marshalls PLC
LSE:MSLH
|
-0.006x |
|
Xref Ltd
AU:XF1
|
-0.317x |
|
Elkop SA
WAR:EKP
|
0.043x |
Annual Cash Flow Conversion Efficiency for Sonoma Pharmaceuticals Inc (2005–2026)
The table below shows the annual cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2026. Review Sonoma Pharmaceuticals Inc (SNOA) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | $3.10 Million | $-3.93 Million | -1.271x | -6269.68% |
| 2025-03-31 | $4.41 Million | $-88.00K | -0.020x | +94.89% |
| 2024-03-31 | $6.14 Million | $-2.40 Million | -0.391x | +49.33% |
| 2023-03-31 | $7.98 Million | $-6.15 Million | -0.771x | -57.89% |
| 2022-03-31 | $8.70 Million | $-4.25 Million | -0.488x | +22.45% |
| 2021-03-31 | $5.36 Million | $-3.38 Million | -0.630x | +22.84% |
| 2020-03-31 | $5.62 Million | $-4.59 Million | -0.816x | +26.92% |
| 2019-03-31 | $10.49 Million | $-11.72 Million | -1.117x | -37.63% |
| 2018-03-31 | $15.33 Million | $-12.44 Million | -0.812x | -112.98% |
| 2017-03-31 | $21.43 Million | $-8.17 Million | -0.381x | +55.82% |
| 2016-03-31 | $10.14 Million | $-8.75 Million | -0.863x | -55.32% |
| 2015-03-31 | $12.05 Million | $-6.69 Million | -0.555x | -36.99% |
| 2014-03-31 | $12.06 Million | $-4.89 Million | -0.405x | -243.85% |
| 2013-03-31 | $4.08 Million | $1.15 Million | 0.282x | -93.93% |
| 2012-03-31 | $-868.00K | $-4.03 Million | 4.645x | +278.40% |
| 2011-03-31 | $1.70 Million | $-4.43 Million | -2.604x | -176.30% |
| 2010-03-31 | $7.04 Million | $-6.64 Million | -0.942x | +87.30% |
| 2009-03-31 | $2.27 Million | $-16.83 Million | -7.418x | -556.02% |
| 2008-03-31 | $15.43 Million | $-17.45 Million | -1.131x | +6.81% |
| 2007-03-31 | $14.90 Million | $-18.08 Million | -1.213x | +56.61% |
| 2006-03-31 | $7.34 Million | $-20.52 Million | -2.796x | +54.50% |
| 2005-03-31 | $2.20 Million | $-13.53 Million | -6.146x | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more